Nolasiban
- Generic Name
- Nolasiban
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N2O3
- CAS Number
- 1477482-19-1
- Unique Ingredient Identifier
- 3765U8A1EC
- Background
Nolasiban is under investigation in clinical trial NCT03081208 (Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI).
Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- ObsEva SA
- Target Recruit Count
- 820
- Registration Number
- NCT03758885
- Locations
- 🇧🇪
Site 1004, Brussels, Belgium
🇨🇿Site 1109, Teplice, Czechia
🇵🇱Site 1706, Warsaw, Poland
Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI
- First Posted Date
- 2017-03-16
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- ObsEva SA
- Target Recruit Count
- 810
- Registration Number
- NCT03081208
- Locations
- 🇭🇺
Investigator ID 1604, Budapest, Hungary
🇧🇪Investigator ID 1003, Brussels, Belgium
🇭🇺Investigator ID 1603, Pécs, Hungary
A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- ObsEva SA
- Target Recruit Count
- 10
- Registration Number
- NCT02326142
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath